Important Note
This article is for educational purposes only. Retatrutide is an investigational medicine and is not approved for use in the United Kingdom or most other countries. This content does not constitute medical advice.
Like other medicines that affect appetite and digestion, retatrutide has been associated with certain side effects in clinical trials. Understanding these effects is an important part of evaluating any new treatment. This page summarises what is currently known from published trial data.
Most Commonly Reported Side Effects
In the TRIUMPH clinical trials, the most frequently reported side effects with retatrutide were gastrointestinal in nature. These included:
- Nausea
- Vomiting
- Diarrhoea
- Constipation
- Decreased appetite
- Abdominal pain or discomfort
These side effects are common with medicines that target GLP-1 receptors and are often more noticeable when treatment is first started or when the dose is increased. In many cases, they tend to lessen over time as the body adjusts.
How Common Are These Side Effects?
From the available data in Phase 2 and Phase 3 trials:
- Gastrointestinal side effects were the most frequent reason for dose reduction or discontinuation in some participants.
- The incidence of these effects appeared to be dose-dependent — meaning higher doses were generally associated with more side effects.
- Some analyses have suggested that retatrutide may cause gastrointestinal side effects at a slightly higher rate compared to dual agonists like tirzepatide, though more data is still needed for confirmation.
It is important to note that individual responses vary. Some people experience mild or no side effects, while others may find them more bothersome.
Other Side Effects Observed
In addition to gastrointestinal effects, other side effects reported in retatrutide studies include:
- Fatigue
- Headache
- Injection site reactions
- Changes in heart rate (usually a modest increase)
These were generally less common than gastrointestinal effects. Researchers continue to monitor these and other potential effects in ongoing trials.
Serious Adverse Events
As with any new medicine in development, serious adverse events are closely monitored. In the TRIUMPH programme, the rate of serious adverse events was generally similar between retatrutide and placebo groups in early reports, but full long-term safety data is still being collected.
Some areas that require further study include:
- Effects on the pancreas and gallbladder
- Potential risk of thyroid tumours (a known concern with some GLP-1 medicines in animal studies)
- Long-term cardiovascular safety
These areas are being actively investigated in ongoing TRIUMPH trials.
Comparison with Other Medicines
When comparing side effect profiles:
| Medicine | Type | Common Side Effects | Notes |
|---|---|---|---|
| Semaglutide | GLP-1 | Nausea, vomiting, diarrhoea | Well-documented profile |
| Tirzepatide | Dual agonist | Nausea, vomiting, diarrhoea | Generally similar to semaglutide |
| Retatrutide | Triple agonist | Nausea, vomiting, diarrhoea (possibly higher rate) | Still under investigation |
Because retatrutide activates three receptors instead of one or two, it is possible that it may have a different side effect profile. However, more complete data from ongoing trials is needed before firm conclusions can be drawn.
Factors That May Influence Side Effects
Several factors can affect how a person experiences side effects, including:
- Starting dose and rate of dose increase
- Individual sensitivity
- Diet and eating habits
- Concurrent medications
In clinical trials, gradual dose escalation was used to help reduce the severity of side effects.
Current Understanding of Safety
As of July 2026, the full long-term safety profile of retatrutide is not yet known. While early trial results have provided useful information, researchers are still collecting data on:
- Effects after one year or more of use
- Safety in different populations (e.g., older adults, people with other health conditions)
- Rare but serious side effects
Until more data is available and regulatory review is complete, retatrutide cannot be considered a fully evaluated treatment option.
Summary
Retatrutide, like other incretin-based medicines, is associated with gastrointestinal side effects, particularly nausea, vomiting, and diarrhoea. These effects appear to be dose-related and often improve over time. Some data suggests these side effects may occur more frequently with retatrutide than with dual agonists, but more research is needed. Serious side effects are being closely monitored in ongoing clinical trials. As with any investigational medicine, the complete safety profile will only become clear after all trial data is analysed and reviewed by regulatory authorities.
References
- ClinicalTrials.gov – TRIUMPH Programme (Eli Lilly). NCT05929066 and related entries.
- Jastreboff, A.M. et al. (2022). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.
- Eli Lilly and Company. (May 2026). Lilly’s triple-agonist retatrutide delivered powerful weight loss in Phase 3 TRIUMPH-1 trial. Press Release.
- Medicines and Healthcare products Regulatory Agency (MHRA) – Guidance on investigational medicines.
For more information, see our main guide on Retatrutide Dosing and Administration
Last Updated: July 2026